Quantcast

Latest Drug Development Stories

2014-08-29 23:09:59

Now approaching the one-year mark since its founding, The Adult Stem Cell Technology Center, LLC (ASCTC) in Boston, Massachusetts has lined-up participation in three conferences focused on stem cells and regenerative medicine over the next two months. At two of the conferences, ASCTC Director James Sherley will provide updates on the company’s progress with development of its new technology for detecting drug candidates that are toxic to tissue stem cells. Boston, MA (PRWEB) August 29,...

2014-08-26 12:29:32

Pre-Clinical Drug Development Targeting Potential Medicinal Applications Starting with Cancer and Neurological Disorders Being Investigated with Progress Report COLORADO SPRINGS, Colo., Aug. 26, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to provide a guidance report on its current pre-clinical drug development programs underway, beginning with the scientific...

2014-08-25 23:10:03

The Manhattan Institute's Project FDA launches series of public discussions on bio-innovation. Boston, MA (PRWEB) August 25, 2014 The Manhattan Institute (MI) and its Project FDA, in partnership with the Tufts Center for the Study of Drug Development, will host the first in a series of public discussions about the reforms necessary to accelerate patient access to life-saving treatments, lower the cost of developing and delivering better treatments, and maintain America’s place as...

Early Step In Body's Counterattack On Virus Blocked By Ebola Protein
2014-08-15 03:16:59

The Mount Sinai Hospital / Mount Sinai School of Medicine Findings provide framework for new drug development efforts One of the human body's first responses to a viral infection is to make and release signaling proteins called interferons, which amplify the immune system response to viruses. Over time, many viruses have evolved to undermine interferon's immune-boosting signal, and a paper published today in the journal Cell Host & Microbe describes a mechanism unique to the Ebola...

2014-08-11 16:28:15

SARASOTA, Fla., Aug. 11, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update. http://photos.prnewswire.com/prnvar/20140811/135143 Second Quarter, 2014: For the three months ended...

2014-08-11 16:28:03

-- FDA Approval of Omidria(TM) Received on May 30, 2014 - SEATTLE, Aug. 11, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014, which include: -- 2Q...

2014-08-11 12:27:41

COLORADO SPRINGS, Colo., Aug. 11, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, signs a binding letter of intent with its existing Michigan partners, increasing Cannabis Science's equity position from 20% to 50.1% in its joint venture in the Michigan medical cannabis and hemp markets, Michigan Green Technologies LLC (MGT). MGT is the leading resource for legislative...

2014-08-05 08:33:27

SOUTH SAN FRANCISCO, Calif., Aug. 5, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the second quarter of 2014, Rigel reported a net loss of $25.4 million, or $0.29 per share, compared to a net loss of $22.8 million, or $0.26 per share, in the same period of 2013. Weighted average shares outstanding for the second quarters of 2014 and 2013 were 87.5 million and 87.1...

2014-08-01 08:26:12

BEVERLY HILLS, Calif., Aug. 1, 2014 /PRNewswire/ -- Crown Baus Capital Corp. (OTC: CBCA), a global acquisition-based conglomerate targeting five primary industries: high-tech incubation, drug development, entertainment/media, education, and financial services, sees this week's Congressional efforts to amend the Controlled Substances Act to permit medical use of cannabis on a nationwide basis as history in the making. This federal medical cannabis legalization effort in Congress...

2014-07-31 16:28:08

SARASOTA, Fla., July 31, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has initiated the development of its lead molecule, Anatabine Citrate, in Europe; and that it has selected Quotient Clinical, The Translational Pharmaceutics Company, based in the United Kingdom (UK) to run its early development programs. http://photos.prnewswire.com/prnvar/20140731/132375 The Company expects to file a Clinical Trial Application (CTA) by the end of...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related